Compare Ecopetrol SA (EC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs McKesson Corporation — how do they compare? Ecopetrol SA trades at $16.93 (market cap $34.09B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 3.1× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (3.91%). Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and McKesson Corporation for 74 Days on average.
| EC | MCK | |
|---|---|---|
Market Cap | $34.09B | $106.14B |
Volume | 952,204 | 794,405 |
Sector | Energy | Health |
52-Week High | $18.26 | $995.69 |
52-Week Low | $8.61 | $725.17 |
Typical Hold Time | 84 Days | 74 Days |
Enterprise Value | $62.65B | $112.67B |
Dividend Yield | 3.91% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.94, down 0.12% with bearish technical signals. The stock shows attractive valuation metrics including P/E of 7.99 and P/S of 0.91, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while the company maintains positive cash flow from operations despite recent earnings misses.
EC presents a value opportunity with discounted multiples but faces operational headwinds. The key investment thesis balances cheap valuation against declining revenue trends and political uncertainty. Risks include continued earnings volatility and government influence, while potential upside exists if new management can stabilize operations and reverse the revenue decline trajectory.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
